Quarterly report pursuant to Section 13 or 15(d)

Segment Information (Tables)

v3.19.1
Segment Information (Tables)
 3 Months Ended
Mar. 31, 2019
Segment Reporting [Abstract]  
Schedule of Segment Reporting Information, by Segment The following tables summarize, for the periods indicated, operating results, from continued operations by reportable segment:
  
 
 
Dermatology
 
 
Pharmaceutical
and
Biotechnology
 
 
 
 
($ in thousands)
 
Products
 
 
Product
 
 
 
 
Three Months Ended March 31, 2019
 
Sales
 
 
Development
 
 
Consolidated
 
Net Revenue
 
$
6,125
 
 
$
352
 
 
$
6,477
 
Direct cost of goods
 
 
(1,884
)
 
 
–
 
 
 
(1,884
)
Sales and marketing costs
 
 
(3,493
)
 
 
–
 
 
 
(3,493
)
Research and development
 
 
–
 
 
 
(23,723
)
 
 
(23,723
)
General and administrative
 
 
(387
)
 
 
(9,598
)
 
 
(9,985
)
Segment income (loss) from operations
 
$
361
 
 
$
(32,969
)
 
$
(32,608
)
Segment assets
 
$
11,079
 
 
$
189,459
 
 
$
200,538
 
 
($ in thousands)
Three Months Ended March 31, 2018
 
Dermatology
Products
Sales
 
 
Pharmaceutical
and
Biotechnology
Product
Development
 
 
Consolidated
 
Net Revenue
 
$
5,509
 
 
$
394
 
 
$
5,903
 
Direct cost of goods
 
 
(1,472
)
 
 
–
 
 
 
(1,472
)
Sales and marketing costs
 
 
(2,764
)
 
 
–
 
 
 
(2,764
)
Research and development
 
 
–
 
 
 
(25,055
)
 
 
(25,055
)
General and administrative
 
 
(397
)
 
 
(10,387
)
 
 
(10,784
)
Segment income (loss) from operations
 
$
876
 
 
$
(35,048
)
 
$
(34,172
)
Segment assets
 
$
11,163
 
 
$
189,560
 
 
$
200,723
 
Assets held for sale
 
 
 
 
 
 
 
 
 
 
64,352
 
Total consolidated
 
 
 
 
 
 
 
 
 
$
265,075